Hormone therapy for menopause
Systemic HRT treats hot flashes and night sweats. Low-dose vaginal therapy treats local vaginal and urinary symptoms; uterus status and health history shape the regimen.
Reviewed by the Rite Aid Health Team Updated September 13, 2026
Take the 3-question HRT options quiz
What would you like to know about?
Not sure where to start?
A few questions can help organize your symptoms and useful next steps.
Start with systemic versus local therapy
More columns are available. Swipe left to see them.
| Systemic hormone therapy | Low-dose vaginal hormone therapy | |
|---|---|---|
| Main purpose | Hot flashes and night sweats; some systemic products also prevent postmenopausal bone loss. | Vaginal dryness, burning, painful sex, and some urinary symptoms from GSM. |
| Forms | Oral tablets, skin patches, gels, sprays, and systemic vaginal rings. | Vaginal cream, tablet/insert, or low-dose ring; vaginal DHEA is a separate local prescription option. |
| Exposure | Circulates throughout the body. | Acts mainly in local tissue with much lower systemic exposure. |
| Uterine protection | Systemic estrogen generally requires adequate progestogen when the uterus is present. | Low-dose vaginal estrogen generally does not require a progestogen, but bleeding still needs evaluation and product guidance applies. |
| Does it treat hot flashes? | Yes. | No. |
Estrogen alone or estrogen plus a progestogen?
If you have had the uterus removed, estrogen alone may be used when otherwise appropriate. If the uterus remains, unopposed systemic estrogen raises endometrial-cancer risk, so adequate progestogen is generally added. Hysterectomy details, endometriosis, prior procedures, and uncommon situations can alter that plan.
Compare oral and transdermal routes
More columns are available. Swipe left to see them.
| Route | Practical feature | Clinical discussion |
|---|---|---|
| Oral estrogen | Familiar daily tablet. | First-pass liver effects influence clotting factors, triglycerides, and other metabolism; personal clot, gallbladder, cardiovascular, and liver risks matter. |
| Transdermal patch, gel, or spray | Delivers estrogen through skin and avoids first-pass liver metabolism. | Observational evidence suggests lower clot risk than oral estrogen, but route does not erase risk or contraindications; skin adherence and transfer instructions matter. |
| Local vaginal | Low dose at the tissue affected by GSM. | Does not treat systemic hot flashes; choose product and coordinate care based on symptoms and health history. |
No route is “best” for everyone. Dose, adherence, cost, insurance, skin reactions, migraine, triglycerides, gallbladder and clot history, and preference can change the choice.
What HRT can treat
Product-specific FDA indications can include:
- moderate-to-severe hot flashes and night sweats;
- moderate-to-severe vulvar or vaginal symptoms due to menopause; and
- prevention of postmenopausal osteoporosis for some systemic products, often with a direction to consider nonestrogen options when prevention is the only goal.
Hormone therapy is not an approved weight-loss treatment, a guaranteed treatment for brain fog, or a way to prevent dementia or cardiovascular disease. The USPSTF recommendation against systemic HRT solely for primary prevention addresses asymptomatic prevention—not treatment of bothersome menopause symptoms.
Who is most likely to have a favorable benefit-risk balance?
The Menopause Society describes a generally favorable balance when all three fit:
- you have bothersome menopause symptoms;
- you are younger than 60 or within 10 years of menopause onset; and
- you do not have a contraindication that changes the choice.
Starting later, or with cardiovascular, clotting, cancer, liver, or unexplained-bleeding history, calls for closer review. There is no universal age at which every person must stop; continued treatment requires periodic review of benefits, risks, dose, route, and goal.
Health history that needs a closer review
Systemic hormone therapy is generally avoided or requires specialist input with unexplained vaginal bleeding, certain estrogen-sensitive cancers, prior blood clot or known thrombophilia, stroke, heart attack, or significant liver disease. High blood pressure, migraine, diabetes, gallbladder disease, endometriosis, smoking, and family history can influence route and product.
Local vaginal treatment has a different exposure and risk discussion. A history of estrogen-dependent breast cancer warrants nonhormone treatment first and coordinated shared decision-making if symptoms remain severe.
Report any bleeding after menopause. Bleeding that begins on therapy also needs evaluation based on its timing, pattern, and regimen rather than being automatically labeled normal.
Almost done
We sent the first email to .
A quick confirmation helps ensure future updates reach the right inbox.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Confirm to receive your HRT updates
Look for HRT explainers, women’s health news, and notifications when Rite Aid HRT care becomes available.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Understand HRT benefits, risks, and choices
Get HRT insights and women’s health news. We’ll notify you when Rite Aid HRT care is available.
Compare options for the symptom that matters to you
Get practical next steps in three questions.
A useful place to start
FDA-approved and compounded hormones are not equivalent
Several FDA-approved estradiol and progesterone products are “bioidentical,” meaning their hormones are chemically identical to those the body produces. FDA approval adds review of safety, effectiveness, manufacturing quality, and labeling.
Compounded hormones may be appropriate when a documented need cannot be met by an approved product, such as an ingredient allergy or unavailable dosage form. They are not FDA-approved, and routine saliva or urine testing to customize a dose has not been shown to improve outcomes.
What changed in FDA labeling on February 12, 2026
In February 2026, the FDA approved label updates for six menopausal hormone products. Statements about cardiovascular disease, breast cancer, and probable dementia were removed from their boxed warnings, the labels' most prominent warning format.
The FDA also requested removal of the blanket “lowest effective dose for the shortest duration” instruction from boxed warnings. Dose and duration should be individualized and reviewed over time. Heart, clot, breast, and uterine risks still matter. Check the current label for the exact product with a clinician or pharmacist, because updates do not apply to every product at once.
Prepare for a useful appointment
Bring:
- the one or two symptoms you most want to improve and their frequency;
- date of last period, pregnancy possibility, contraception, and any unexpected bleeding;
- whether the uterus and ovaries are present;
- cancer, clot, stroke, heart, liver, gallbladder, migraine, bone, and mood history;
- all prescriptions, nonprescription products, and supplements; and
- route preferences, cost constraints, and treatment concerns.
Ask what benefit to expect, the most important personal risk, how soon to reassess, and what symptom or side effect should trigger contact. Blood tests can help assess ovarian function or investigate overlapping symptoms when your history calls for them.
If hormones do not fit or you prefer another approach, compare nonhormone and symptom-specific treatment options.
The menopause treatment priorities quiz can help you organize the symptom, safety, and practical questions to bring to that conversation. It does not determine whether a treatment is safe for you.
When care is urgent
Contact a clinician for any bleeding after menopause or unexplained bleeding on treatment. Seek emergency care for chest pain, severe shortness of breath, coughing blood, fainting, sudden one-sided leg swelling, a sudden severe headache, facial droop, trouble speaking, or one-sided weakness or numbness.
What is the difference between HRT and menopausal hormone therapy?
HRT and menopausal hormone therapy usually mean the same treatment in menopause care.
Almost done
We sent the first email to .
A quick confirmation helps ensure future updates reach the right inbox.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Confirm to receive your HRT updates
Look for HRT explainers, women’s health news, and notifications when Rite Aid HRT care becomes available.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Understand HRT benefits, risks, and choices
Get HRT insights and women’s health news. We’ll notify you when Rite Aid HRT care is available.
Sources and references
- FDA: Requested menopause hormone label changes — boxed-warning wording and product-specific updates.
- ACOG: Hormone Therapy for Menopause — systemic/local therapy, uterine protection, benefits, risks, and route context.
- The Menopause Society: Hormone Therapy and 2022 Position Statement index — benefit-risk timing, indications, and continuation.
- FDA: February 12, 2026 menopausal hormone therapy labeling changes — exact scope and date of approved changes.
- USPSTF: Hormone Therapy for Primary Prevention of Chronic Conditions — prevention-only boundary.
- ACOG: Compounded Bioidentical Menopausal Hormone Therapy — FDA-approved versus compounded products.